Welcome to our dedicated page for Roivant Sciences SEC filings (Ticker: ROIV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sorting through Roivant Sciences’ SEC documents can feel like wading into clinical trial protocol. Pipeline updates, cash-runway figures, and milestone payments are scattered across hundreds of pages—yet a single sentence can move ROIV’s share price. If you have ever asked, “Where do I find Roivant Sciences insider trading Form 4 transactions before the market reacts?” you know the challenge.
Stock Titan solves it. Our AI instantly parses every submission—whether a dense Roivant Sciences annual report 10-K simplified for pipeline strategy, a fresh Roivant Sciences quarterly earnings report 10-Q filing detailing R&D spend, or an urgent Roivant Sciences 8-K material events explained that discloses trial data. Interactive summaries highlight what matters: Phase III read-outs, collaboration revenue, and liquidity. You can even set real-time alerts for Roivant Sciences Form 4 insider transactions real-time to monitor executive sentiment.
Searching for specifics? Our coverage spans every form investors ask about: 10-K to see cash runway; 10-Q for quarter-over-quarter expense trends; 8-K for FDA designations; the Roivant Sciences proxy statement executive compensation for option grants; and the indispensable Roivant Sciences executive stock transactions Form 4 for ownership changes. Each document comes with plain-English notes—perfect for understanding Roivant Sciences SEC documents with AI and speeding due-diligence. Quickly generate a Roivant Sciences earnings report filing analysis, track disclosure history, or export data for models—no more CTRL-F marathons.
Whether you’re an analyst gauging dilution risk or a healthcare investor timing entry around data catalysts, our platform keeps every question answered and every filing at your fingertips—updated the moment it hits EDGAR.
Roivant Sciences Ltd. (ROIV) insider filing shows Eric Venker, President & Immunovant CEO, reporting option awards and multiple share sales. The Form 4 discloses grants of stock options exercisable at $3.85 covering 1,562,374 options in total (1,000,000 on 09/19/2025; 462,374 and 100,000 on 09/22/2025) with an April 19, 2032 expiration and vesting tied to a 04/20/2022 commencement schedule. The filing also reports open-market sales totaling 1,711,000 common shares across 09/19–09/23/2025 at weighted-average prices disclosed in ranges (examples: $14.95, $14.99, $15.01, $14.83), some effected pursuant to a Rule 10b5-1 trading plan adopted June 25, 2024. Post-transactions, reported beneficial ownership figures for common stock and underlying options are shown on the form.
Roivant Sciences Ltd. (ROIV) filed a Rule 144 notice disclosing a proposed sale of 611,079 shares of common stock, scheduled approximately 09/23/2025 through Charles Schwab & Co. The filing lists an aggregate market value of $9,129,520.26 and reports 682,881,743 shares outstanding. The shares were acquired as equity compensation on 01/20/2023 for services rendered. The filer also reported three recent sales by Eric Venker totaling 1,200,000 shares between 07/21/2025 and 09/19/2025 with combined gross proceeds shown. The notice includes the standard representation that the seller has no undisclosed material adverse information.
Roivant Sciences Ltd. (ROIV) filed a Form 144 notifying a proposed sale of 316,182 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $4,741,054.24, scheduled approximately for 09/22/2025. The shares were reported acquired the same day via a stock option exercise and paid for in cash. The filing also discloses prior sales by Eric Venker totaling 883,818 shares across July–September 2025 with combined gross proceeds of $12,644,412.21. The notice includes the sellers representation there is no undisclosed material adverse information.
Roivant Sciences Ltd. (ROIV) insider notice under Rule 144: This Form 144 reports a proposed sale of 100,000 common shares by a person for whose account the securities are to be sold, using Rockefeller Financial LLC as broker on 09/22/2025. The filing states an aggregate market value of $1,501,338.85 for the shares and notes there are 682,881,743 shares outstanding.
The shares were acquired the same day through an options exercise (grant date 04/20/2022) from Roivant Sciences Ltd., with payment by wire. The filer also discloses two prior sales in the past three months: 100,000 shares sold on 08/20/2025 (gross proceeds $1,172,120.12) and 100,000 shares sold on 07/21/2025 (gross proceeds $1,151,941.91).
Roivant Sciences Ltd. (ROIV) filing a Form 144 notifies an intended sale of 683,818 common shares via Morgan Stanley Smith Barney on 09/19/2025, with an aggregate market value reported as $10,220,412.21. The shares were acquired and paid for on 09/19/2025 through a stock option exercise with cash payment. The filer also reported three prior open-market sales by Eric Venker totaling 300,000 shares during June–August 2025 for combined gross proceeds of $3,452,000.00. The notice includes the standard representation that the seller is unaware of undisclosed material adverse information.
Matthew Gline, listed as Director and CEO of Roivant Sciences Ltd. (ROIV), reported a purchase of 3,315 common shares on 09/18/2025 at a weighted average price of $15.07 per share. After this transaction the filing shows Mr. Gline beneficially owns 17,287,081 common shares. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Gline.
Roivant Sciences Ltd. reported the results of shareholder votes demonstrating routine corporate governance outcomes. Shareholders re-elected the individuals named to serve as Class I directors to hold office until the annual general meeting following the fiscal year ending March 31, 2028. Shareholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers as disclosed in the proxy statement. The advisory vote tallied 316,651,402 votes in favor, 203,244,184 against and 64,550,276 abstentions; there were 44,227,813 broker non-votes reported. The filing includes the cover page interactive data file as an exhibit.
Roivant Sciences director Vivek Ramaswamy reported multiple open-market sales of the company's common shares on September 3–5, 2025. The Form 4 shows he disposed of 1,195,000 shares on 09/03/2025 at a weighted-average price of $12.50, 194,933 shares on 09/04/2025 at $12.92 weighted-average, and 385,816 shares on 09/05/2025 at $12.96 weighted-average, for total reported disposals of 1,775,749 shares. After these transactions he beneficially owns 35,508,359 shares directly and holds an additional 13,357,857 shares indirectly. Footnotes state the reported prices are weighted averages reflecting multiple transactions in specified price ranges, and the form is signed by an attorney-in-fact.
FAQ
What is the current stock price of Roivant Sciences (ROIV)?
What is the market cap of Roivant Sciences (ROIV)?
